Latest Hoffmann-La Roche Stories
Healthhound.org is going to try the Alli weight loss pill. The management at the site have assembled a team that will be trying out the pill. Houston, TX. (PRWEB) December 15, 2011 Healthhound.org have just assembled a team that will be taking the Alli weight loss pill for the next 6 weeks and will be reporting back on their findings to readers. The management at the site want their readers to see what this pill can do first hand to a normal group of people with regard to weight loss....
LYNBROOK, N.Y., Dec. 9, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) in the U.S. and XIAPEX(®) in Europe and Eurasia, today announced the appointment of George Gould, Esq., to its Board of Directors effective December 6, 2011. Mr. Gould, an attorney, is Principal of George M. Gould, LLC, and of counsel to Gibbons PC. He has deep expertise in...
<font size="2" face="Arial"> </font><font size="2" face="Arial">INDIANAPOLIS</font>, Dec. 5, 2011 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has filed a 510(k) submission to the U.S. Food and Drug Administration (FDA) for a fully automated, total vitamin D assay (25-hydroxyvitamin D) for use on Roche's full portfolio of laboratory analyzers.* The Elecsys® vitamin D test can be combined with routine testing on...
INCLINE VILLAGE, Nev., Nov. 9, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the third quarter ended September 30, 2011. (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO) Revenues Total revenues for the third quarter of 2011 were $83.8 million, compared to $86.4 million for the same period of 2010, a three percent year-over-year decrease. Total revenues for the nine months ended September 30, 2011, were $289.2 million,...
NUTLEY, N.J., Nov. 7, 2011 /PRNewswire/ -- Roche announced today that Pamela Carroll, PhD, has joined the company as Nutley Oncology Discovery Site Head and Global Head, Pathways Biology within Pharma Research and Early Development (pRED). Pam joins Roche from Belfer Institute of Applied Cancer Sciences at Dana Farber Cancer Institute, Harvard Medical School, where she was Head of Research and a member of the Senior Leadership Team. As Oncology Discovery Site Head for Nutley, Pam will be...
HAYWARD, Calif., Nov. 7, 2011 /PRNewswire/ -- Molecular diagnostics company GenturaDx today announces that it has been awarded two additional patents from the United States Patent Office related to the company's IDbox(TM), it's fully-integrated molecular diagnostics platform. These two new patents (U.S. Patent Nos. 7,910,062 and 8,029,746) relate to GenturaDx's proprietary method of manipulating paramagnetic particles inside a closed cartridge for the purpose of purifying nucleic acids, and...
INDIANAPOLIS and MONTREAL, Oct. 12, 2011 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the U.S. launch of the latest addition to the company's real-time PCR portfolio of LightCycler® instruments for use in research, the LightCycler Nano real-time PCR system. Roche Applied Science made the announcement in conjunction with the start of the 61st annual meeting of the American Society of Human Genetics in Montreal. The new LightCycler Nano instrument shares the...
MADISON, Wisconsin, October 10, 2011 /PRNewswire/ -- With the decreasing cost and increasing throughput of sequencing, researchers require a high-performance, cost-effective sample preparation pipeline for targeted sequencing. To enable researchers to more readily match targeted sequencing sample preparation throughput to the ever increasing throughput of next-generation sequencing, Roche NimbleGen (SIX: RO, ROG; OTCQX: RHHBY) [http://www.roche.com/investors.htm ] announces...
ROTKREUZ, Switzerland and ASNIERES, France, October 4, 2011 /PRNewswire/ -- Roche Professional Diagnostics and Diagnostica Stago announced today that the companies have decided to pursue separate paths in the business of Laboratory Coagulation in the territories where Roche distributed the Stago product range. The exclusive sales of Stago products by Roche will continue throughout the entire year of 2011. With the exception of Japan, where Roche Diagnostics Japan will continue...
NUTLEY, N.J., Sept. 30, 2011 /PRNewswire/ -- Roche announced today the opening of a new state-of-the-art clinical supply manufacturing facility on its campus in Nutley, N.J. The Roche Center of Excellence produces dosage forms of highly potent compounds for preclinical safety studies, and Phase 1 and 2 clinical studies. The 17,000 square foot facility houses specialized equipment to process potent compounds into medicines for clinical trials. "This is a vitally important milestone for the...
